The appointment of a new CEO with a strong background in the medical technology industry, particularly from a reputable company like Johnson & Johnson, is likely to be viewed positively by investors. Makatsaria's experience and leadership skills are expected to contribute significantly to LivaNova's strategic growth plans, potentially leading to increased investor confidence and a positive impact on the stock price in the short term.